iSchemaView RAPID

by RapidAI (formerly iSchemaView)  · Based in United States → — AI beyond the algorithm™
Emergency Medicine Neurology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Contact for pricing
Regulatory Status Disclosed

Overview

iSchemaView RAPID (developed by RapidAI, formerly iSchemaView) is a clinical artificial intelligence platform designed to automate the processing and analysis of medical imaging for neurovascular and vascular conditions. The platform assists in the rapid assessment of acute conditions, including ischemic stroke, hemorrhagic stroke, subdural hematoma, and aneurysms, by providing automated triage, localization, and quantitative analysis.

The software is primarily utilized by radiologists, neurologists, neurosurgeons, and emergency department physicians within hospital networks, comprehensive stroke centers, and hub-and-spoke healthcare systems. It supports clinical decision-making by analyzing non-contrast computed tomography (NCCT), CT angiography (CTA), CT perfusion (CTP), and magnetic resonance imaging (MRI) scans.

RAPID integrates directly into existing clinical workflows, connecting with Picture Archiving and Communication Systems (PACS), Electronic Health Records (EHR), and mobile communication applications. Key capabilities include:

  • Automated Triage and Prioritization: Identifies and flags suspected large vessel occlusions (LVO) and intracranial hemorrhages (ICH) to prioritize urgent cases on the radiology worklist.
  • Quantitative Perfusion Analysis: Generates color-coded perfusion maps to measure cerebral blood flow, volume, and transit time, helping to identify salvageable brain tissue.
  • Volumetric and Anatomical Measurements: Automatically calculates hematoma volume, midline shift, and aneurysm dimensions.
  • Care Team Collaboration: Facilitates real-time image sharing and communication across multidisciplinary teams to coordinate patient transfers and interventions.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-driven detection of Large Vessel Occlusion (LVO)
  • AI-driven detection of Intracranial Hemorrhage (ICH)
  • Automated CT Perfusion (CTP) analysis
  • Automated CT Angiography (CTA) analysis
  • Automated MRI Diffusion and Perfusion analysis
  • ASPECTS scoring from CT scans
  • 3D reconstruction of vasculature
  • Real-time viewing and analysis of brain images
  • Workflow and communication capabilities (mobile app, email, PACS integration)
  • Edge-to-cloud platform architecture

Use Cases

  • Acute stroke diagnosis and treatment decision making
  • Patient selection for endovascular thrombectomy
  • Triage and transfer decisions for stroke patients
  • Monitoring and analysis of cerebrovascular conditions
  • Aneurysm management (SurgicalPreview module)
  • Clinical trials and research support

What Physicians Need to Know

Evidence Base
iSchemaView RAPID is built on an extensive evidence base, having been utilized in landmark stroke trials such as SWIFT PRIME, EXTEND IA, DAWN, DEFUSE 3, EXTEND, and TIMELESS. These trials have significantly influenced stroke treatment guidelines from organizations like the American Heart Association and American Stroke Association, leading to the expansion of the treatment window for mechanical thrombectomy up to 24 hours for select patients. The Canadian Stroke Best Practice Recommendations for Acute Stroke Management were also updated in 2018 to recommend automated imaging software like RAPID for patient selection. The platform's AI framework incorporates deep learning, machine learning, and expert feature extraction. A vast body of publications highlights its impact on cerebrovascular imaging advancements and research.
Clinical Validation Studies
RAPID is a clinically validated imaging solution for stroke diagnostic support, deployed in over 1,000 stroke centers and approximately ten large-scale international trials globally. Performance validation testing has consistently demonstrated accurate representation of key processing parameters. Specific modules have undergone rigorous validation: RAPID ICH, for instance, was developed and validated using over a thousand CT scans, achieving sensitivity and specificity greater than 90% for detecting brain hemorrhages. RAPID ASPECTS has been validated in patients with known MCA or ICA occlusion, showing improved agreement among non-neuroradiologists. The RAPID LVO module demonstrated a sensitivity of 0.970 and a specificity of 0.956 in a standalone performance study. A comprehensive review included 2 cohort studies and 11 diagnostic accuracy studies evaluating RapidAI for detecting stroke, specifically large vessel occlusion (LVO) and intracranial hemorrhage (ICH). Studies have reported RapidAI's sensitivity for LVO at 0.62 and specificity at 0.927.
Alert Fatigue Management
While specific features explicitly named 'alert fatigue management' are not prominently detailed in the available literature for iSchemaView RAPID, the system inherently addresses this by providing workflow triage and prioritizing notifications for suspected intracranial hemorrhage (ICH) and large vessel occlusion (LVO). This prioritization helps clinicians focus on critical cases.
Override Rate Data
Specific override rate data for iSchemaView RAPID is not readily available in the provided information. However, for the RAPID ASPECTS module, clinicians have the ability to manually adjust the automated score based on other clinical factors and their discretion, indicating a mechanism for clinical oversight and potential modification of the system's output.
Differential Diagnosis Support
RAPID provides robust differential diagnosis support within the context of stroke. It offers automated analysis of CT and MRI images to distinguish between irreversibly damaged brain tissue (infarct core) and salvageable tissue (ischemic penumbra). The platform includes various modules that aid in differentiating stroke types and severity, such as RAPID CTP for perfusion analysis, RAPID MRI for diffusion and perfusion, RAPID CTA for vessel visualization, RAPID ASPECTS for early ischemic change scoring, RAPID ICH for detecting intracranial hemorrhage, RAPID LVO for identifying large vessel occlusion, and RAPID SDH for subdural hemorrhage. This comprehensive suite of tools assists in distinguishing between ischemic and hemorrhagic strokes and identifying the extent of damage.
Guideline Update Frequency
While iSchemaView RAPID itself does not have a 'guideline update frequency,' its development and validation are intrinsically linked to the evolution of stroke treatment guidelines. The platform has been instrumental in clinical trials that have directly led to updates in major stroke guidelines, such as those from the American Heart Association and American Stroke Association, expanding treatment windows for interventions like mechanical thrombectomy. The company actively engages in research that shapes these clinical recommendations.
Clinical Workflow Integration
RAPID is designed for seamless integration into clinical workflows. It is a fully automated software platform where images can be auto-sent for processing in 2 minutes or less. Results are immediately delivered to PACS, email, and the dedicated RAPID mobile app. The platform integrates with mobile communication platforms like Pulsara, enabling real-time sharing of images and stroke information across the entire stroke team. It supports 'hub and spoke' models for regional stroke networks, allowing a centralized server to process images and push results back to local PACS systems. Furthermore, RAPID Angio integrates with Siemens Healthineers syngo DynaCT Multiphase for direct evaluation in the angiography suite, streamlining acute stroke patient assessment. The system provides workflow triage by flagging and communicating suspected positive findings of ICH and LVO, enhancing care collaboration and efficiency.
Decision Audit Trail
Direct information specifically detailing a 'Decision Audit Trail' feature for iSchemaView RAPID, which tracks physician decisions based on the tool's output, is not explicitly provided in the search results. However, as a medical device, it is expected to adhere to regulatory standards that typically include internal logging and data retention practices. The system does allow for data purging at a frequency dependent on the site.
Physician Tip

Leverage iSchemaView RAPID's rapid, automated analysis for time-sensitive stroke cases to quickly identify infarct core and penumbra, and differentiate between ischemic and hemorrhagic stroke types. Utilize the comprehensive multi-modal imaging analysis (CTP, MRI, CTA, ASPECTS, ICH, LVO, SDH) for a thorough assessment. Integrate the mobile app and communication features for efficient team collaboration and faster decision-making. Remember that while the software provides automated scores and insights, clinical judgment, and integration with other patient-specific factors remain paramount. Be aware of its role in expanding treatment windows for thrombectomy, allowing for timely intervention in eligible patients.

iSchemaView RAPID boasts an open API infrastructure, facilitating seamless integration with various hospital systems. Key integrations include Picture Archiving and Communication Systems (PACS), mobile communication platforms like Pulsara for real-time team collaboration, and the dedicated RAPID Mobile App for on-the-go access to results. It also integrates with specific imaging systems, such as Siemens Healthineers syngo DynaCT Multiphase for angiography suite applications. The platform supports 'hub and spoke' models, enabling efficient data flow and result dissemination across regional stroke networks.

Details

Category Neurology AI, Radiology & Imaging AI
Pricing Contact for pricing
  • Annual Hub Licensing Fee; One Time Set up and Training Fee; Reduced Annual Licensing Fee for Spoke sites
DeploymentHybrid (On-premise server and cloud-based edge-to-cloud platform)
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

The iSchemaView RAPID (K182130, cleared 12/27/2018) is an image processing software package for viewing, processing, and analysis of CT Perfusion (CT-P), CT Angiography (CTA), and MRI (Diffusion Weighted MRI and Dynamic Analysis Module) datasets. It aids in physician diagnosis and the selection of acute stroke patients for endovascular thrombectomy.
Integrations
EHR Not specified
Specialties Emergency Medicine, Neurology, Radiology

What the Web Says

iSchemaView RAPID (now RapidAI) is a widely adopted AI-powered platform in healthcare, primarily for stroke detection and management. Reviews from physicians and healthcare IT professionals generally highlight its effectiveness in improving patient outcomes by providing rapid and accurate analysis of medical images, leading to faster treatment decisions. The platform's ability to automate and streamline workflows is a recurring positive theme, although some users note the initial setup and integration can be complex.

Overall: Positive

Strengths

  • Significantly reduces time to treatment for stroke patients
  • High accuracy in identifying treatable stroke cases (LVO, ICH)
  • Automates image analysis and provides critical data quickly
  • Improves inter-hospital communication and patient transfer efficiency
  • User-friendly interface once integrated into workflow
  • Backed by extensive clinical validation and research

Limitations

  • Initial integration and setup can be complex and time-consuming
  • Cost can be a barrier for smaller institutions
  • Requires robust IT infrastructure and support
  • Potential for alert fatigue if not configured properly
  • Learning curve for new users, especially with advanced features
  • Limited information on customer support responsiveness in some reviews

Based on reviews from: RapidAI Website (case studies, testimonials), G2, Capterra, Reddit (r/medicine, r/radiology), Healthcare IT News, Journal of NeuroInterventional Surgery (JNIS)

Last updated: 2026-07-21

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate iSchemaView RAPID

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

RapidAI Press Releases
RapidAI Highlights Research Depth and Industry Leadership at ISC 2026 With 28 Clinical Abstracts
RapidAI announced 28 scientific abstracts accepted at the International Stroke Conference (ISC) 2026, showcasing new clinical research on AI-driven advancements in aneurysm detection, stroke interpretation, and enterprise imaging efficiency.
2026-02
RapidAI Press Releases
RapidAI Extends the Reach of Deep Clinical AI with Five New FDA Clearances
RapidAI received U.S. FDA clearance for five new imaging modules: Rapid DeltaFuseu2122, Rapid LMVO, Rapid MLS, Rapid OH, and Rapid Aortic for measurement, significantly expanding the Rapid Enterpriseu2122 Platform.
2025-11
RapidAI Press Releases
RapidAI Earns FDA Clearance for Rapid Aortic, Bringing AI-Driven Aortic Measurements and Surveillance to Care Teams
RapidAI announced U.S. FDA clearance for Aortic Management, part of the Rapid Aortic product, a comprehensive deep clinical AI solution for acute assessment and longitudinal management of aortic disease.
2025-11
RapidAI Press Releases
RapidAI and AWS Strengthen Relationship: Accelerate Global Deployment of Deep Clinical AI
RapidAI and Amazon Web Services (AWS) announced a strengthened working relationship to accelerate the global adoption and scalability of deep clinical AI in healthcare through co-development and go-to-market alignment.
2025-12
RapidAI Press Releases
Lumina 3D by RapidAI Named to TIME's List of the Best Inventions of 2025
RapidAI's Lumina 3Du2122, built on the Rapid Enterpriseu2122 Platform, was named to TIME's List of the Best Inventions of 2025, recognizing its innovation in changing how we live, work, and care for one another.
2025-10
RapidAI Press Releases
RapidAI Announces $75 Million Growth Investment Led by Vista Credit Partners
RapidAI announced $75 million in Series C funding led by Vista Credit Partners, intended to fuel continued innovation in its advanced clinical decision and workflow support technology and further establish its leadership in clinical AI solutions.
2023-07
Stroke: Vascular and Interventional Neurology (American Heart Association Journals)
RapidAI Compared With Human Readers of Acute Stroke Imaging for Detection of Intracranial Vessel Occlusion
This study concluded that experienced human readers of acute stroke imaging can identify large vessel occlusions (LVOs) and medium vessel occlusions (MVOs) with higher accuracy than RapidAI software in a real-world setting.
2024-01
Canadian Journal of Health Technologies
RapidAI for Stroke Detection
This review indicates that RapidAI has the potential to improve acute stroke care by creating efficiencies in the diagnostic process, but more robust studies are needed to confirm its impact on patient outcomes and cost-effectiveness.
2024-12

Videos

Product demos, reviews, and walkthroughs for iSchemaView RAPID.

No videos found. Search YouTube directly

View all on YouTube

Frequently Asked Questions

RAPID seamlessly integrates with existing PACS and DICOM systems, automatically processing CT and MRI images (CTP, CTA, MRI, NCCT, ASPECTS) to generate easy-to-interpret maps and analyses. It delivers rapid notifications via PACS, email, and a mobile app, aiding in timely clinical decision-making, patient triage, and inter-hospital communication for acute stroke care.
Yes, various modules of the RAPID platform, including Rapid CTA, Rapid ASPECTS, Rapid NCCT Stroke, and Rapid ICH, have received FDA clearance. The system also complies with DICOM standards and adheres to stringent data security and quality management certifications such as HIPAA, GDPR, ISO 13485, and ISO 27001.
Key alternatives in the market for AI-driven stroke imaging analysis include platforms such as Viz.ai, Brainomix, and Aidoc. These systems also offer automated processing of stroke imaging to assist in diagnosis and treatment decisions.
While specific pricing details are not publicly disclosed, the model often involves server installation costs, annual licensing fees, and one-time setup and training fees. A hub-and-spoke model may offer reduced annual licensing fees for spoke sites, and the overall cost impact can be influenced by factors like scanner volume and integration complexity.
RAPID is intended as a decision support tool and not for primary image interpretation, requiring confirmation with standard radiologist review. Limitations can include false positives or negatives due to imaging artifacts like patient motion or metal, incorrect vessel segmentation, or confounding pathologies. Some studies also suggest that experienced human readers may exhibit higher accuracy in detecting large and medium vessel occlusions compared to RapidAI software.
RapidAI implements robust security measures including AES-256 encryption for data at rest and TLS for data in transit. The platform is HIPAA and GDPR compliant, and holds ISO 27001 certification, demonstrating a commitment to protecting patient information through secure development practices, real-time monitoring, and role-based access control.
RapidAI offers comprehensive end-to-end support to ensure confident platform usage. This includes 24/7 customer support via email and phone, along with access to educational resources such as expert guides and learning materials.

Related Tools

DETECT-ME/CFS project
ME/CFS Research Foundation (Sponsor: Federal Ministry of Health (BMG))
Clinical Decision Support & Reference
The DETECT-ME/CFS project is developing an AI-supported clinical decision support system to improve the rapid and reliable diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Neurotrack
Neurotrack
Clinical Decision Support & Reference
Neurotrack is a cognitive care enablement platform that provides clinically validated, FDA class II device assessments and care planning support to identify and manage cognitive decline and dementia earlier and with greater accuracy.
LesionQuant
CorTechs Labs
Neurology AI
LesionQuant, an FDA-approved AI product by CorTechs Labs, is particularly useful for patients with multiple sclerosis. It provides brain structure data and quantifies the number, size, and location of lesions, comparing them to prior studies.
ExcelsiusGPS
Globus Medical
Neurology AI
ExcelsiusGPS™ is the first and only robotic navigation platform on the market that offers a comprehensive approach to spine and cranial procedures, from start to finish. The system enables repeatable and accurate trajectory alignment and navigation for placing screws, interbody implants, and cranial instruments.
Paid
Onera SleepMap
Onera B.V.
Neurology AI
Onera SleepMap is an AI-powered sleep analysis software that processes polysomnography data, part of Onera Health's innovative patch-based system for at-home and in-lab sleep studies. The system aims to make clinical-grade sleep diagnostics more accessible and user-friendly, providing comprehensive data comparable to traditional in-lab PSG.
Per-test pricing
JLK-NCCT
JLK-NCCT
Clinical Decision Support & Reference
JLK-NCCT is an AI software designed to assist in the analysis of non-contrast CT brain scans for the detection of acute ischemic stroke.

See all Neurology AI tools →

More from RapidAI (formerly iSchemaView)

Rapid
RapidAI (formerly iSchemaView)
Neurology AI
RapidAI is an AI-driven medical imaging analysis and coordinated care platform that empowers healthcare teams to rapidly, precisely, and confidently manage life-threatening conditions, especially acute stroke, through advanced CT and MRI image processing.
Contact for pricing
Rapid CTA 360
RapidAI (formerly iSchemaView)
Neurology AI
Rapid CTA 360 by RapidAI (formerly iSchemaView) is an AI-powered imaging solution providing automated 3D CTA reconstructions for rapid and precise stroke diagnosis and treatment planning, enhancing visibility of occlusions and collateral flow.
Contact vendor for pricing
Rapid LVO
RapidAI (formerly iSchemaView)
Neurology AI
Rapid LVO by RapidAI is an FDA-cleared AI tool for the fast and accurate detection of Large Vessel Occlusions (LVOs) in acute stroke patients using CTA imaging, streamlining triage and care coordination.
Contact vendor for pricing.
Rapid PE Triage and Notification (PETN)
RapidAI (formerly iSchemaView)
Cardiology AI
Rapid PE Triage and Notification (PETN) by RapidAI is an AI-powered software that analyzes CTPA images to rapidly identify and notify clinicians of suspected central pulmonary embolisms, streamlining workflow and accelerating patient care pathways.
Contact for pricing

View company profile →

Suggest an Edit → | Last Verified: 2026-04-21 | First Added: 2026-04-21
AI Tool Finder
AI-powered search. Results may not be comprehensive.